Schizophrenia Clinical Trial
Official title:
Parallel Effects of Ketamine and Schizophrenia on Neurocognitive Function
Verified date | February 2016 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This study investigates the common features of electrophysiological measures in schizophrenia and effects of NMDA antagonist ketamine in healthy volunteers.
Status | Completed |
Enrollment | 33 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 21 Years to 45 Years |
Eligibility |
Subjects for the Ketamine experiment(Healthy control experiment): Inclusion Criteria: 1. Male or female 2. 21-45 years old 3. Deemed healthy by the Structured Clinical Interview for DSM-NP (SCID-NP) and collateral information. Subjects will need to provide the name of a person, preferably a family member, whom the research team can contact to corroborate information. Exclusion Criteria: 1. Lifetime diagnosis of DSM-IV substance dependence (except caffeine and nicotine). 2. Substance abuse, as per clinical judgment, in the past 1 year. 3. Current or past DSM-IV Axis-I diagnosis. 4. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up. 5. A hearing deficit greater than 30 dB in both ears detected using a Welch-Allyn audioscope (500, 1000, 2000 and 4000 Hz threshold will be evaluated) at screening. 6. Major current or recent (<6 weeks) stressors. 7. History of counseling, except if counseling was for a life circumstance disorder (e.g., bereavement, divorce) or in the opinion of the investigator, is not clinically significant. 8. Lifetime history of treatment with any psychotropic medications for > 1 month duration suggestive of psychiatric illness. 9. Current or past Axis I diagnosis of schizophrenia or bipolar disorder in first-degree relatives. 10. Any medication that could interfere with either the safety of the study and/or the outcome measures. 11. Use of any illicit substances in the 4 weeks prior to beginning study participation. 12. Any history indicating learning disability, mental retardation, or attention deficit disorder. 13. History of head injury with loss of consciousness greater than fifteen minutes. 14. Any other condition or medication, which in the opinion of the investigator would preclude participation in the study. 15. Non-English speaking. 16. Known sensitivity to ketamine. Subjects for the Schizophrenia experiment: Inclusion Criteria for control subjects: 1. Male or female 2. 21-45 years old 3. No past or present Axis I diagnosis, as determined by the SCID-NP Exclusion Criteria for control subjects: 1. Lifetime diagnosis of DSM-IV substance dependence (except caffeine and nicotine). 2. Substance abuse, as per clinical judgment, in the past 1 year 3. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological. 4. A hearing deficit greater than 30dB in both ears detected using a Welch-Allyn audioscope (500, 1000, 2000 and 4000 Hz threshold will be evaluated) at screening. 5. Axis I diagnosis of schizophrenia or bipolar disorder in first-degree relatives. 6. History of head injury with loss of consciousness greater than fifteen minutes 7. Any other condition or medication, which in the opinion of the investigator would preclude participation in the study. 8. Non-English speaking. Inclusion Criteria for patients: 1. Male or female 2. 21-45 years old 3. Diagnosed with DSM-IV schizophrenia based on a SCID-IP interview for patients. 4. Stable dose of antipsychotic medications for at least 2 weeks prior to beginning study participation. 5. Score either in the 1-3 (high functioning) range or in the 5-7 (low functioning) range of the Global Functioning Scale from the MSIF based on a screening interview. Exclusion Criteria: 1. Lifetime diagnosis of DSM-IV substance dependence (except caffeine and nicotine). 2. Substance abuse, as per clinical judgment, in the past 1 year 3. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological. 4. A hearing deficit greater than 30dB in both ears detected using a Welch-Allyn audioscope (500, 1000, 2000 and 4000 Hz threshold will be evaluated) at screening. 5. History of head injury with loss of consciousness greater than fifteen minutes. 6. Any other condition or medication, which in the opinion of the investigator would preclude participation in the study. 7. Non-English speaking. |
Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | VHA CT | West Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | P300, an ERP measure | Baseline and repeat assessment following ketamine | No | |
Secondary | (Mismatch Negativity) MMN | Baseline and repeat assessment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |